WO1984003698A1 - Compound - Google Patents
Compound Download PDFInfo
- Publication number
- WO1984003698A1 WO1984003698A1 PCT/SE1984/000089 SE8400089W WO8403698A1 WO 1984003698 A1 WO1984003698 A1 WO 1984003698A1 SE 8400089 W SE8400089 W SE 8400089W WO 8403698 A1 WO8403698 A1 WO 8403698A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- fluorescence
- lanthanide
- bio
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 4
- 230000008878 coupling Effects 0.000 claims abstract description 4
- 238000010168 coupling process Methods 0.000 claims abstract description 4
- 238000005859 coupling reaction Methods 0.000 claims abstract description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 2
- -1 p-isothiocyanatophenyl group Chemical group 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 claims 1
- 150000002540 isothiocyanates Chemical class 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 150000002602 lanthanoids Chemical class 0.000 description 20
- 229910052747 lanthanoid Inorganic materials 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 229910001868 water Inorganic materials 0.000 description 16
- 239000013522 chelant Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 229910052693 Europium Inorganic materials 0.000 description 10
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229960003330 pentetic acid Drugs 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- HXHMECGFHPUMNM-UHFFFAOYSA-N 1-n-(2-aminoethyl)-3-(4-isothiocyanatophenyl)propane-1,2-diamine Chemical compound NCCNCC(N)CC1=CC=C(N=C=S)C=C1 HXHMECGFHPUMNM-UHFFFAOYSA-N 0.000 description 1
- NDTXYMAGPAKHBA-UHFFFAOYSA-N 1-n-(2-aminoethyl)-3-(4-nitrophenyl)propane-1,2-diamine Chemical compound NCCNCC(N)CC1=CC=C([N+]([O-])=O)C=C1 NDTXYMAGPAKHBA-UHFFFAOYSA-N 0.000 description 1
- OEAHSWCPGQHDBE-UHFFFAOYSA-N 2-(4-aminophenyl)-2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical class NC1=CC=C(C(N(CCN(CC(O)=O)CC(O)=O)CC(O)=O)C(O)=O)C=C1 OEAHSWCPGQHDBE-UHFFFAOYSA-N 0.000 description 1
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 1
- WVVLURYIQCXPIV-UHFFFAOYSA-N 4,4,4-trifluoro-1-naphthalen-2-ylbutane-1,3-dione Chemical compound C1=CC=CC2=CC(C(=O)CC(=O)C(F)(F)F)=CC=C21 WVVLURYIQCXPIV-UHFFFAOYSA-N 0.000 description 1
- POLIXZIAIMAECK-UHFFFAOYSA-N 4-[2-(2,6-dioxomorpholin-4-yl)ethyl]morpholine-2,6-dione Chemical compound C1C(=O)OC(=O)CN1CCN1CC(=O)OC(=O)C1 POLIXZIAIMAECK-UHFFFAOYSA-N 0.000 description 1
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- ZFVMPHOLEJVJPJ-UHFFFAOYSA-N acetic acid;azane Chemical class N.N.CC(O)=O.CC(O)=O.CC(O)=O ZFVMPHOLEJVJPJ-UHFFFAOYSA-N 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- ZXVOCOLRQJZVBW-UHFFFAOYSA-N azane;ethanol Chemical compound N.CCO ZXVOCOLRQJZVBW-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- ZMBHCYHQLYEYDV-UHFFFAOYSA-N trioctylphosphine oxide Chemical compound CCCCCCCCP(=O)(CCCCCCCC)CCCCCCCC ZMBHCYHQLYEYDV-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
- C07F9/3817—Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/40—Rare earth chelates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/13—Tracers or tags
Definitions
- the present invention refers to a compound.
- Immunoassay is a field in which the sensitivity of the analysis method often is of decisive importance as the amount of analyte in different biological liquids usually is very low.
- radioisotopes have been widely used as labels in immunoassays despite the dis- advantages caused by their use.
- a very intense research has been carried out with the aim of replacing the radioisotopes with labels giving at least the same or a higher sensitivity than the isotopes.
- Fluorescent molecules have in these connections been presented as one of the most potential alternatives to radioisotopes.
- Comprehensive surveys have recently been published, which give a good general view of fluoroimmunoanalytical determinations known at present (see Smith et al. (1981) Ann. Clin. Biochem. 18, 253-274, Ullman (1981) "Recent Advances in Fluorescence Immunoassay techniques").
- time-resolved fluorescence makes it, however, possible to separate the specific fluorescence of the label from the disturbing, unspecific background fluorescence.
- time-resolved fluorescence when following biospecific affinity reactions is described in the U.S. Patent No. 4,374,120 and the European patent application No. 82850077.7.
- time-resolved fluorescence the fluorescent label is excited by means of a light pulse of a short duration and the fluorescence is not detected until a certain period of time has elapsed from the excitation pulse.
- 4,374,120 comprises a lanthanide chelate formed by a lanthanide and an aromatic ⁇ -diketone, the lanthanide being bound to antigen, hapten, antibody, nucleic acid or polynucleotide via an EDTA-analogue so that a fluorescent lanthanide complex is formed.
- the fluorescence decay time of the label is long, 50 - 1000 ⁇ sec, which makes it most suitable for the time-resolved detection principle.
- the fluorescence from the label can either be measured when the marker is bound to antigen, hapten, antibody, nucleic acid or polynucleotide, or the lanthanide can under suitably chosen circumstances be released from these by dissociating the bond between the lanthanide and the EDTA-analogue, the fluorescence being caused in solution in the presence of an aromatic ⁇ -diketone, a synergistic compound and a detergent which together with the lanthanide form a micellar system having a fluorescence which is characteristic of the lanthanide (European Patent Application No. 82850077.7).
- the lanthanide should form a fluorescent chelate and on the other hand it should be bound to a bioorganic molecule, which is an antigen, a hapten, an antibody, a nucleic acid or a polynucleotide, in order to be usable as a label in biospecific affinity reactions.
- the primary ligand only acts as an intermediary for the binding of the lanthanide to the bio-organic molecule.
- the EDTA analogue mentioned earlier (U.S. Patent No. 4,374,120) follows the latter principle.
- Aminophenyl-EDTA-Eu can e.g. be diazotated and thereafter be coupled to tyrosine or histidine residues in a protein.
- the synthesized protein-EDTA-Eu complex gives, however, upon excitation a very low lanthanide fluorescence of a long decay time, since the primary ligand does not absorb and transfer the necessary excitation energy to the lanthanide.
- the ligand functions excellently in biospecific affinity reactions according to the principles which are described in the U.S. Patent No. 4,374,120 and the European Patent Application No. 82850077.7.
- Ethylenediamine tetraacetic acid is a well known and commonly used compound, which under suitable conditions forms stable chelates with a large number of metal ions (see Ringbom (1964) Kompleksometrisk analys) .
- the chelate forming characteristics of the molecule can be utilized to bind e.g. lanthanides to bio-organic molecules for use in bio-specific affinity reactions, if a covalent coupling of the ligand to the bio-organic molecule can be carried out. This has been done by e.g.
- an aminophenyl-EDTA derivative can be synthesized which can be used to bind the EDTA structure to the bioorganic molecule (see Sundberg et al, U.S. Patent 3,994,966).
- EDTA diethylenetriaminepentaacetic acid
- DTPA diethylenetriaminepentaacetic acid
- DTPA has also been coupled to protein by the use of a cyclic anhydride of the molecule, four carboxyl groups then remaining for chelating (see: Hnatowich et al. (1982) Int. J. Appl. Radiat. Isot. 33, 327-332).
- the object of the present invention is to provide a chelating compound, which strongly chelates i.a. lanthanides, but which also comprises active functional groups which makes it possible to bind the metal chelate to a bio-organic molecule comprising e.g. hapten, antigen, nucleic acid or antibody.
- a chelating compound which strongly chelates i.a. lanthanides, but which also comprises active functional groups which makes it possible to bind the metal chelate to a bio-organic molecule comprising e.g. hapten, antigen, nucleic acid or antibody.
- the drawing shows a typical AFP determination with duplicate standards for seven different concentrations.
- R is a 2 to 8 atoms long covalent bridge comprising alkylene groups
- Y comprises carboxylic or phosphonic acid and the number varies depending on n and m.
- X is an active functional group which permits coupling to a bio-organic molecule and comprises e.g. an aromatic ring comprising a NH 2 , OH, COOH or NCS group; n and m are 0 or 1.
- X can change place with one of the Y functions in the molecule.
- the chelating compounds can be synthesized in the following ways:
- Step 1 2.0 g diethylenetriamine is dissolved in 25 ml toluene and 1.0 g 4-nitrobenzylbromide dissolved in 25 ml toluene is added. The reaction mixture is stirred for 3 hours at room temperature. The precipitate is filtrated and the toluene phase is extracted with water. The water phase is extracted with chloroform which is evaporated to dryness. The final product consists of a yellow syrup (0.85 g, 77% yield).
- Step 2 The mixture of N 1 - and N 2 - (4-nitrobenzyl)-diethylenetriamine is dissolved in water.
- the water solution is made alkaline (pH 9-11) with 7 M KOH solution and is heated during stirring to 50°C.
- a water solution of bromoacetic acid (2.5 g) is added slowly and pH is kept between 9-11 by means of the KOH solution.
- the stirring and the heating are continued for at least 4 hours, KOH solution being added now and then to keep pH in between 9 and 11.
- the reaction mixture is acidified (pH about 1) , the insignificant precipitate appearing on the cooling, then being filtrated away.
- the solution is evaporated to a smaller volume, a salt then beinq precipitated, the precipitation of which is facilitated by adding acetone.
- the solution is evaporated to dryness and an impure raw product is obtained (3.1 g, containing about 50% of the desired compound).
- the product is purified by.means of preparative liquid chromatography (Waters PrepPAK - 500/C 18 , with H 2 O) , then also the different isomers being separated from each other.
- TLC silica gel; acetonitrile/water 4:1; R f for N 1 compound as Eu 3+ chelate 0.25 and N 2 compound 0.30.
- Step 4 2.3 g of N 2 - (4-aminobenzyl)-diethylenetriamine-N 1 , N 1 , N 3 , N 3 - tetraacetic acid is dissolved in about 15 ml of water and the solution is added to a reagent mixture containing 1.7 g of thiophosgene, 15 ml of chloroform and 1 g of sodium hydrogen carbonate. The reaction mixture is strongly stirred for about 20 minutes in room temperature. The phases are separated and the water phase is washed with chloroform (3 x 5 ml) , it then being evaporated to dryness and the obtained product is washed with ethanol. Final product 2.2 g, yield 83%.
- TLC Silica gel; acetonitrile/water 4 :1; R 1 f for N and
- the other compounds mentioned can be synthesized in a corresponding way starting from the corresponding polyalkylene-polyamine.
- the carboxylic groups can also be replaced by phosphonic acid (K. MOEDRITZER -R.R. IRANI. J.Org.Chem. 31, 1603 (1966).
- the applicability of the invention is illustrated below by means of a non-limiting example of execution.
- Example 1 Determination of alphaphetoprotein (AFP).
- p-ITC-B-DTTA-Eu was added to an anti-AFP solution (0.2 mg in 200 ⁇ l PBS) at 0°C and the pH of the solution was adjusted to 9.5 by means of 10 ⁇ l of 1 M Na 2 CO 3 .
- the molar ratio between chelate and antibody was 60:1.
- the reaction mixture was incubated over night, whereupon the antibody conjugate was purified from free unreacted label by means of gel filtration on a Sephadex G-50 column (Pharmacia). The degree of conjugation was determined by measuring the europium fluorescence and it was found to be about 7 Eu/IgG. Immunoas say
- Polystyrene tubes were coated with anti-AFP by incubating the tubes over night at room temperature with 250 ⁇ l of a solution containing 1 ⁇ g of anti-AFP in 50 mM K 2 HPO 4 + 9 g/l of NaCl.
- the tube surface was saturated with 250 ⁇ l of a solution containing 0.5% of BSA in Tris-HCl buffer, pH 7.70 (2 hours at room temperature). After washing the tubes were used for the immunoassay.
- 25 ⁇ l serum samplesor corresponding standards were incubated for 1 hour in the coated tubes together with 50 ng of europium labelled anti-AFP which had been added in 225 ⁇ l of Tris-HCl buffer, pH 7.7 containing 0.9% NaCl, 0.05% NaN 3 , 0.5% BSA, 0.05% bovine gammaglobuline, 0.01% Tween-40 and 20 ⁇ M DTPA. After incubation the tubes were aspirated and washed three times with 2 ml of physiological sodium chloride solution containing 0.05% NaN 3 .
- the solution dissociates europium from the chelate, a new fluorescent chelate thus being formed in the micellar phase, the amount of which is proportional to the time-resolved fluorescence signal obtained and the amount of europium released.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
Compound having structure (I), where R is a direct chain or branched alkylene group comprising 2-8 carbon atoms; n and m are 0 or 1, Y is a carboxylic or phosphonic acid, and X is an active funcitional group which permits covalent coupling to a bio-organic molecule.
Description
Compound.
TECHNICAL FIELD
The present invention refers to a compound.
BACKGROUND ART
Immunoassay is a field in which the sensitivity of the analysis method often is of decisive importance as the amount of analyte in different biological liquids usually is very low. As a result of this radioisotopes have been widely used as labels in immunoassays despite the dis- advantages caused by their use. At the same time, however, a very intense research has been carried out with the aim of replacing the radioisotopes with labels giving at least the same or a higher sensitivity than the isotopes. Fluorescent molecules have in these connections been presented as one of the most potential alternatives to radioisotopes. Comprehensive surveys have recently been published, which give a good general view of fluoroimmunoanalytical determinations known at present (see Smith et al. (1981) Ann. Clin. Biochem. 18, 253-274, Ullman (1981) "Recent Advances in Fluorescence Immunoassay techniques").
The sensitivity of the fluorescent labels in immunoassay, in spite of the fact that it is theoretically very high, has been seriously limited by a high background fluorescence. Usually, it has been possible to reduce the background fluorescence, so that a desired sensitivity could be obtained. The above mentioned surveys also describe the limitations which have made the use of conventional fluorescent labels difficult in immunoassay of analytes which require a high sensitivity corresponding to that which can be obtained with radioisotopes.
The use of time-resolved fluorescence (see Soini et al (1979) Clin. Chem. 25, 353-361) makes it, however, possible to
separate the specific fluorescence of the label from the disturbing, unspecific background fluorescence. The principle of the use of time-resolved fluorescence when following biospecific affinity reactions is described in the U.S. Patent No. 4,374,120 and the European patent application No. 82850077.7. In time-resolved fluorescence the fluorescent label is excited by means of a light pulse of a short duration and the fluorescence is not detected until a certain period of time has elapsed from the excitation pulse. During the time which passes between excitation and detection, the fluorescence from any interfering sources will decay, so that only the signal from the label usable for time-resolved fluorescence is detected. Such a label should have as high fluorescence as possible, a relatively long emission wave-length, a large Stoke's shift and a chemical structure which makes it possible to couple the label covalently to antigens, haptens, antibodies nucleic acids and polynucleotides. A fluorescence label, which fulfils the above mentioned requirements (U.S. Patent No. 4,374,120) comprises a lanthanide chelate formed by a lanthanide and an aromatic β-diketone, the lanthanide being bound to antigen, hapten, antibody, nucleic acid or polynucleotide via an EDTA-analogue so that a fluorescent lanthanide complex is formed. The fluorescence decay time of the label is long, 50 - 1000 μsec, which makes it most suitable for the time-resolved detection principle. The fluorescence from the label can either be measured when the marker is bound to antigen, hapten, antibody, nucleic acid or polynucleotide, or the lanthanide can under suitably chosen circumstances be released from these by dissociating the bond between the lanthanide and the EDTA-analogue, the fluorescence being caused in solution in the presence of an aromatic β-diketone, a synergistic compound and a detergent which together with the lanthanide form a micellar system having a fluorescence which is characteristic of the lanthanide (European Patent Application No. 82850077.7).
In the use of lanthanides as labels in biospecific affinity
reactions two functions can in principle be distinguished. On the one hand, the lanthanide should form a fluorescent chelate and on the other hand it should be bound to a bioorganic molecule, which is an antigen, a hapten, an antibody, a nucleic acid or a polynucleotide, in order to be usable as a label in biospecific affinity reactions.
The prerequisites for the formation of a fluorescent lanthanide chelate are described in the European Patent Application No. 83850244.1. A specific controlled binding of a lanthanide to a bio-organic molecule has proved to be difficult even if a number of alternative solutions has been tested. In such a binding it is desirable that the lanthanide is bound to the bio-organic molecule with a very high affinity and that the binding is kinetically stable. The primary ligand which is covalently bound to the bioorganic molecule and which also chelates the lanthanide, can also absorb the excitation energy which is then transferred to the lanthanide according to the principles which are described in the European Patent Application No. 83850244.1, or alternatively the primary ligand only acts as an intermediary for the binding of the lanthanide to the bio-organic molecule. The EDTA analogue mentioned earlier (U.S. Patent No. 4,374,120) follows the latter principle. Aminophenyl-EDTA-Eu can e.g. be diazotated and thereafter be coupled to tyrosine or histidine residues in a protein. The synthesized protein-EDTA-Eu complex gives, however, upon excitation a very low lanthanide fluorescence of a long decay time, since the primary ligand does not absorb and transfer the necessary excitation energy to the lanthanide. In spite of this the ligand functions excellently in biospecific affinity reactions according to the principles which are described in the U.S. Patent No. 4,374,120 and the European Patent Application No. 82850077.7.
Ethylenediamine tetraacetic acid (EDTA) is a well known and commonly used compound, which under suitable conditions forms stable chelates with a large number of metal ions
(see Ringbom (1964) Kompleksometrisk analys) . The chelate forming characteristics of the molecule can be utilized to bind e.g. lanthanides to bio-organic molecules for use in bio-specific affinity reactions, if a covalent coupling of the ligand to the bio-organic molecule can be carried out. This has been done by e.g. synthesizing an EDTA dianhydride, which is coupled to a suitable bio-organic molecule, a diaminetriacetic acid derivative of the molecule is, then, obtained when the fourth carboxyl group is used for the conjugation (see. Wieder et al, U.S. Patent 4,353,751).
Moreover, an aminophenyl-EDTA derivative can be synthesized which can be used to bind the EDTA structure to the bioorganic molecule (see Sundberg et al, U.S. Patent 3,994,966). There are, however, other compounds than EDTA. which form stable chelates with metal ions (see Ringbom (1964) Kompleksometrisk analys). One of them, diethylenetriaminepentaacetic acid (DTPA) has e.g. been used to bind radioisotopes in connection with the examination of kidney functions (see Klopper et al. (1972) J.Nucl. Med. 13, 107-110). DTPA has also been coupled to protein by the use of a cyclic anhydride of the molecule, four carboxyl groups then remaining for chelating (see: Hnatowich et al. (1982) Int. J. Appl. Radiat. Isot. 33, 327-332).
DISCLOSURE OF INVENTION
The object of the present invention is to provide a chelating compound, which strongly chelates i.a. lanthanides, but which also comprises active functional groups which makes it possible to bind the metal chelate to a bio-organic molecule comprising e.g. hapten, antigen, nucleic acid or antibody. The characteristic features of the invention are apparent from the claims attached to the specification.
BRIEF DESCRIPTION OF DRAWING
The drawing shows a typical AFP determination with duplicate standards for seven different concentrations.
DETAILED DESCRIPTION
Compounds according to the invention can be derived starting from the following basic structure
in which R is a 2 to 8 atoms long covalent bridge comprising alkylene groups Y comprises carboxylic or phosphonic acid and the number varies depending on n and m. X is an active functional group which permits coupling to a bio-organic molecule and comprises e.g. an aromatic ring comprising a NH2, OH, COOH or NCS group; n and m are 0 or 1.
X can change place with one of the Y functions in the molecule.
The chelating compounds can be synthesized in the following ways:
Step 1: 2.0 g diethylenetriamine is dissolved in 25 ml toluene and 1.0 g 4-nitrobenzylbromide dissolved in 25 ml toluene is added. The reaction mixture is stirred for 3 hours at room temperature. The precipitate is filtrated and the toluene phase is extracted with water. The water
phase is extracted with chloroform which is evaporated to dryness. The final product consists of a yellow syrup (0.85 g, 77% yield).
TLC: silica gel; ammonia ethanol 1:4; Rf for N1 compound 0.38 and for N2 compound 0.29. 1H-N.M.R. (CDCl3) : δ = 7.8 ( q, 4 H, ), 3.7 tor N2
and 3,9 for N1 compound (S, 2H, -N),
2,7 (m, 8H,-CH2CH2-)1-,6 (S, 2H-NH-&-NH2)
U.V. (H2O) : λ max = 273 nm
Step 2: The mixture of N1- and N2- (4-nitrobenzyl)-diethylenetriamine is dissolved in water. The water solution is made alkaline (pH 9-11) with 7 M KOH solution and is heated during stirring to 50°C. A water solution of bromoacetic acid (2.5 g) is added slowly and pH is kept between 9-11 by means of the KOH solution. After the addition the stirring and the heating (50°C) are continued for at least 4 hours, KOH solution being added now and then to keep pH in between 9 and 11. The reaction mixture is acidified (pH about 1) , the insignificant precipitate appearing on the cooling, then being filtrated away. The solution is evaporated to a smaller volume, a salt then beinq precipitated, the precipitation of which is facilitated by adding acetone. The solution is evaporated to dryness and an impure raw product is obtained (3.1 g, containing about 50% of the desired compound). The product is purified by.means of preparative liquid chromatography (Waters PrepPAK - 500/C18, with H2O) , then also the different isomers being separated from each other.
TLC: silica gel; acetonitrile/water 4:1; Rf for N1 compound
0.16 and for N2 compound 0.33. 13C-N.M.R. (D2O) : δ=52.4 & 52.6 (-CH2CH2-) , 57.8 (-CH2COOH)
N2 compound) U.V. (H2O) : λmax = 269 nm I.R. (KBr) : Vmax = 1740, 1530, 1350 cm-1
Step 3: 2.0 g of a compound from the previous synthesis step is dissolved in 50 ml water and 0.2 g of palladium on activated carbon (5%) is added to the solution in a pressure reactor. The reactor is cooled to 0 - +5ºC and is washed with nitrogen gas and hydrogen gas. The reduction takes place at 0 - +5°C at about 1 MPa (pressure above atmospheric). The reaction is followed on thin layer plates (acetonitrile water 4:1), by means of a liquid chromatography (HPLC) or UV-spectrophotometry. Final product 1.7 g, yield 89%.
TLC: silica gel; acetonitrile/water 4:1; Rf for N1 compound as Eu3+ chelate 0.25 and N2 compound 0.30.
183 (-COOH) (for N compound as Eu3+ chelate) U.V. (H2O) : λ max = 284 & 238 nm (~1:8) I.R. (KBr) : V max = 1580-1640, 1400 cm-1
Step 4: 2.3 g of N2 - (4-aminobenzyl)-diethylenetriamine-N1, N1, N3 , N3 - tetraacetic acid is dissolved in about 15 ml of water and the solution is added to a reagent mixture containing 1.7 g of thiophosgene, 15 ml of chloroform and 1 g of sodium hydrogen carbonate. The reaction mixture is strongly stirred for about 20 minutes in room temperature. The phases are separated and the water phase is washed with chloroform (3 x 5 ml) , it then being evaporated to dryness and the obtained product is washed with ethanol. Final product 2.2 g, yield 83%.
TLC: Silica gel; acetonitrile/water 4 :1; R 1 f for N and
N2 compounds 0.45
U.V. (H20) : λ max = 268 x 280 nm ( ~1:1) I.R. (KBr): V max = 2000-2200 cm-1
Reaction scheme: Step 1:
Step 4:
Corresponding isothiocyanato derivative.
The other compounds mentioned can be synthesized in a corresponding way starting from the corresponding polyalkylene-polyamine. The carboxylic groups can also be replaced by phosphonic acid (K. MOEDRITZER -R.R. IRANI. J.Org.Chem. 31, 1603 (1966). The applicability of the invention is illustrated below by means of a non-limiting example of execution.
Example 1. Determination of alphaphetoprotein (AFP). The chelating compound N2 - (p - isothiocyanato benzyl)diethylenetriamine - N1, N1 , N3, N3 - tetraacetic acid
(p - ITC - B - DTTA) is used to chelate europium and to bind the europium chelate to a monoclonal anti-AFP antibody. The europium labelled antibody was used in the immunoassay of AFP.
Labelling the antibody with europium
p-ITC-B-DTTA-Eu was added to an anti-AFP solution (0.2 mg in 200 μl PBS) at 0°C and the pH of the solution was adjusted to 9.5 by means of 10 μl of 1 M Na2CO3. The molar ratio between chelate and antibody was 60:1. The reaction mixture was incubated over night, whereupon the antibody conjugate was purified from free unreacted label by means of gel filtration on a Sephadex G-50 column (Pharmacia). The degree of conjugation was determined by measuring the europium fluorescence and it was found to be about 7 Eu/IgG.
Immunoas say
Polystyrene tubes were coated with anti-AFP by incubating the tubes over night at room temperature with 250 μl of a solution containing 1 μg of anti-AFP in 50 mM K2HPO4 + 9 g/l of NaCl. The tube surface was saturated with 250 μl of a solution containing 0.5% of BSA in Tris-HCl buffer, pH 7.70 (2 hours at room temperature). After washing the tubes were used for the immunoassay.
25 μl serum samplesor corresponding standards were incubated for 1 hour in the coated tubes together with 50 ng of europium labelled anti-AFP which had been added in 225 μl of Tris-HCl buffer, pH 7.7 containing 0.9% NaCl, 0.05% NaN3, 0.5% BSA, 0.05% bovine gammaglobuline, 0.01% Tween-40 and 20 μM DTPA. After incubation the tubes were aspirated and washed three times with 2 ml of physiological sodium chloride solution containing 0.05% NaN3.
Quantitation of europium by means of time-resolved fluorescence.
The amount of europium, which via the chelate and the labelled antibody has been bound in the immunometric analysis to the surface of the tube, was quantitated by adding 0.5 ml enhancement solution (15 μM β-naphthoyltrifluoroacetone, 50 μM. trioctylphosphine oxide, 0.1 % of Triton X-100 in phthalate-acetate-buffer pH 3.2). The solution dissociates europium from the chelate, a new fluorescent chelate thus being formed in the micellar phase, the amount of which is proportional to the time-resolved fluorescence signal obtained and the amount of europium released.
Result
The result from a typical AFP determination with duplicate standards for seven different concentrations is shown in Table 1 and on the attached drawing.
Claims
1. Compound having the following structure:
, where
- R is a direct chain or branched alkylene group comprising 2-8 carbon atoms,
- n and m are 0 or 1,
- Y is a carboxylic or phosphonic acid, and
- X is an active functional group which permits covalent coupling to a bio-organic molecule.
2. Compound according to claim 1, wherein the active functional group comprises an alkylene group with
2-8 carbon atoms, a phenyl ring or an aromatic hetero- cyclic ring which has a NH2-, HO-, -COOH, isothiocyanate or isocyanate group as a substituent.
3. Compound according to claim 1, wherein X can change place with one of the Y-functions in the molecule.
4. Compound according to claim 1, wherein
- R is an ethylene group,
- n = m = O,
- Y is carboxylic acid, and
- X is either a p-aminophenyl or a p-isothiocyanatophenyl group.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE8484901128T DE3462252D1 (en) | 1983-03-15 | 1984-03-13 | Compound |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8301395A SE8301395L (en) | 1983-03-15 | 1983-03-15 | KELATIZING COMPOUNDS WITH FUNCTIONAL GROUPS WHICH ALLOW COVALENT COUPLING TO BIO-ORGANIC MOLECULES |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1984003698A1 true WO1984003698A1 (en) | 1984-09-27 |
Family
ID=20350368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1984/000089 WO1984003698A1 (en) | 1983-03-15 | 1984-03-13 | Compound |
Country Status (6)
Country | Link |
---|---|
US (1) | US4808541A (en) |
EP (1) | EP0139675B1 (en) |
JP (1) | JPS60500767A (en) |
DE (1) | DE3462252D1 (en) |
SE (1) | SE8301395L (en) |
WO (1) | WO1984003698A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987004523A1 (en) * | 1986-01-23 | 1987-07-30 | Robert Stephen Davidson | Binding assay and assay reagent |
WO1988002784A1 (en) * | 1986-10-17 | 1988-04-21 | Wallac Oy | Hybridization assay and means to be used in the assay |
EP0328529A1 (en) * | 1986-09-05 | 1989-08-23 | Otto A Gansow | Method for preparing polysubstituted diethylenetriaminepentaacetic acids. |
WO1989012631A1 (en) * | 1988-06-24 | 1989-12-28 | The Dow Chemical Company | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
EP0374947A1 (en) * | 1988-12-23 | 1990-06-27 | The Dow Chemical Company | Process for preparing isothiocyanato functionalized metal complexes |
WO1990014881A2 (en) * | 1989-05-26 | 1990-12-13 | Akzo N.V. | Chelating agents for attaching metal ions to proteins |
US5099069A (en) * | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
EP0484989A1 (en) * | 1986-09-05 | 1992-05-13 | GANSOW, Otto A. | Polysubstituted diethylenetriamine chelates for forming a metal-chelate-protein conjugate |
EP0540975A1 (en) * | 1991-11-06 | 1993-05-12 | Bayer Ag | Diethylenetriamine derivatives and their use for diagnostic and therapeutic purposes |
EP0570022A2 (en) | 1988-10-31 | 1993-11-18 | The Dow Chemical Company | Chelants possessing ortho ligating functionality and complexes thereof |
WO1995018832A1 (en) * | 1994-01-07 | 1995-07-13 | Akzo Nobel N.V. | New polyaminocarboxylate chelators |
US5488126A (en) * | 1989-05-26 | 1996-01-30 | Akzo Nobel N.V. | Bifunctional chelating agents |
US5652361A (en) * | 1988-06-24 | 1997-07-29 | The Dow Chemical Company | Macrocyclic ligands and complexes |
US5756065A (en) * | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
US5808003A (en) * | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
US5811526A (en) * | 1986-01-23 | 1998-09-22 | Alusuisse Holdings A.G. | Binding assay and assay reagent |
WO2001036973A2 (en) * | 1999-11-16 | 2001-05-25 | Otto Wolfbeis | Method for solubilising optical markers |
US11845976B2 (en) | 2019-08-27 | 2023-12-19 | SeLux Diagnostics, Inc. | Systems and methods for performing antimicrobial susceptibility testing |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5064633A (en) * | 1984-06-04 | 1991-11-12 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes, their formulations and use |
IT1213029B (en) * | 1986-01-30 | 1989-12-07 | Bracco Ind Chimica Spa | PARAMAGNETIC METAL ION CHELATES. |
US5006643A (en) * | 1987-06-24 | 1991-04-09 | The Dow Chemical Company | Process for preparing isothiocyanato functionalized metal complexes |
SE8703682L (en) * | 1987-09-24 | 1989-03-25 | Wallac Oy | HOMOGENIC DETERMINATION METHOD USING AFFINITY REACTIONS |
US4962045A (en) * | 1988-05-02 | 1990-10-09 | The Perkin-Elmer Corporation | Time-resolved fluorimetric detection of lanthanide labeled nucleotides |
GB8927503D0 (en) * | 1989-12-04 | 1990-02-07 | Kronem Systems Inc | Enzyme-amplified lanthanide chelate luminescence |
EP0493745A1 (en) * | 1990-12-21 | 1992-07-08 | Dojindo Laboratories | Fluorescent compound, complex, reagent, and specific binding assay employing said reagent |
AU653012B2 (en) * | 1991-02-14 | 1994-09-15 | Microscan, Inc. | Novel lanthanide chelate-conjugated oligonucleotides |
FI88654C (en) * | 1991-03-15 | 1993-06-10 | Datacity Center Oy | Fluorescenshoejningsmetod |
DE19507820A1 (en) | 1995-02-21 | 1996-08-22 | Schering Ag | Novel substituted DTPA derivatives, their metal complexes, pharmaceutical compositions containing these complexes, their use in diagnostics, and methods for producing the complexes and compositions |
US7745142B2 (en) * | 1997-09-15 | 2010-06-29 | Molecular Devices Corporation | Molecular modification assays |
US20050227294A1 (en) * | 1997-09-15 | 2005-10-13 | Molecular Devices Corporation | Molecular modification assays involving lipids |
US7632651B2 (en) * | 1997-09-15 | 2009-12-15 | Mds Analytical Technologies (Us) Inc. | Molecular modification assays |
US7070921B2 (en) | 2000-04-28 | 2006-07-04 | Molecular Devices Corporation | Molecular modification assays |
US6030840A (en) * | 1998-06-15 | 2000-02-29 | Nen Life Sciences, Inc. | Neutral enhancement of lanthanides for time resolved fluorescence |
AU5871000A (en) * | 1999-06-11 | 2001-01-02 | Paul G. Abrams | High dose radionuclide complexes for bone marrow suppression |
US7094885B2 (en) * | 1999-07-11 | 2006-08-22 | Neorx Corporation | Skeletal-targeted radiation to treat bone-associated pathologies |
US6440389B1 (en) * | 2000-07-19 | 2002-08-27 | The General Hospital Corporation | Fluorescent agents for real-time measurement of organ function |
JP2004536034A (en) | 2001-01-08 | 2004-12-02 | ネオルクス コーポレイション | Therapeutic and diagnostic compounds, compositions and methods |
US20030215391A1 (en) * | 2001-07-19 | 2003-11-20 | Carlos Rabito | Fluorescent agents for real-time measurement of organ function |
US7211440B2 (en) | 2002-03-08 | 2007-05-01 | Wallac Oy | Dissociative fluorescence enhancement assay |
CN1910293B (en) | 2003-10-23 | 2011-04-13 | 伊洛默格生物科学公司 | Detection of mutations in a gene associated with resistance to viral infection, OASI |
DE102004022628A1 (en) * | 2004-05-07 | 2005-12-15 | Sensient Imaging Technologies Gmbh | FRET bioassay |
EP1805188A4 (en) * | 2004-09-30 | 2010-03-03 | Mds Analytical Technologies Us | Luminescent lanthanide complexes |
US7482444B2 (en) | 2006-03-13 | 2009-01-27 | Wallac Oy | Terminating substrates for DNA polymerases |
US8778614B2 (en) | 2010-08-24 | 2014-07-15 | Enzo Life Sciences, Inc. | Assays for detecting modified compounds |
GB201018361D0 (en) | 2010-11-01 | 2010-12-15 | Thompson Edward J | Fluorometry |
CN107083319A (en) | 2012-03-16 | 2017-08-22 | 统计诊断与创新有限公司 | Testing cassete with integrated delivery module |
FI125111B (en) * | 2013-11-19 | 2015-06-15 | Kemira Oyj | A method for analyzing a sample comprising first and second anticaking agents |
FI125102B (en) * | 2013-11-19 | 2015-06-15 | Kemira Oyj | A method for determining a crust inhibitor in a sample |
AU2017210215B2 (en) | 2016-01-21 | 2022-09-08 | SeLux Diagnostics, Inc. | Methods for rapid antimicrobial susceptibility testing |
US9834808B2 (en) | 2016-01-21 | 2017-12-05 | SeLux Diagnostics, Inc. | Methods for rapid antibiotic susceptibility testing |
CN110603333A (en) | 2016-12-23 | 2019-12-20 | 赛录科试诊断公司 | Method for improved rapid antimicrobial sensitivity testing |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB723316A (en) * | 1951-06-11 | 1955-02-09 | Frederick Charles Bersworth | Substituted alkylene polyamine acetic acid compounds |
DE2015022A1 (en) * | 1970-03-28 | 1971-10-28 | Joh. A. Benckiser Gmbh, Chemische Fabrik, 6700 Ludwigshafen | Agents for stabilizing the hardness of water, especially in cleaning solutions |
DE2233273A1 (en) * | 1971-07-07 | 1973-01-11 | Monsanto Co | CONDENSED POLYALKYLENE POLYAMINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE |
DE2150994A1 (en) * | 1971-10-13 | 1973-04-19 | Basf Ag | Aminopolycarboxylic acid salts - of alkalis in pure form by reacting alkali cyanide with formaldehyde or n-contg prim alcohol |
FR2196992A1 (en) * | 1972-08-21 | 1974-03-22 | Ciba Geigy Ag | |
DE2319047A1 (en) * | 1973-04-14 | 1974-10-31 | Hoechst Ag | ZWITTERIONIC PHOSPHORUS COMPOUNDS AND PROCESS FOR THE PREPARATION |
DE2357278A1 (en) * | 1973-11-16 | 1975-05-28 | Hoechst Ag | ANTIMICROBIAL INTERFACE-ACTIVE MEDIUM |
DE2611813A1 (en) * | 1975-03-20 | 1976-09-30 | Monsanto Co | IMINOALKYLIMINOPHOSPHONATE, METHOD FOR THEIR PRODUCTION AND USE |
US3994966A (en) * | 1972-09-28 | 1976-11-30 | The Board Of Trustees Of The Leland Stanford Junior University | Chelating agents |
DE2751943A1 (en) * | 1976-11-26 | 1978-06-01 | Ciba Geigy Ag | NEW AMINO-PHOSPHONATE |
DE2851898A1 (en) * | 1977-12-02 | 1979-06-07 | Montedison Spa | NEW DERIVATIVES OF N,N'-4-PIPERIDYL-TETRAALKYL-SUBSTITUTED ALKYLENEDIAMINE AND MATERIALS CONTAINING THEM |
DE2918842A1 (en) * | 1978-05-31 | 1979-12-13 | Rexolin Chem Ab | CHELATING AGENTS AND THEIR USE |
EP0071564A1 (en) * | 1981-07-24 | 1983-02-09 | Schering Aktiengesellschaft | Paramagnetic complex salts, their preparation and their use in NMR diagnostics |
US4374120A (en) * | 1979-03-08 | 1983-02-15 | Wallac Oy | Fluorescence spectroscopy assay means with fluorescent chelate of a lanthanide |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH572461A5 (en) * | 1970-12-18 | 1976-02-13 | Basf Ag | |
DE2523209A1 (en) * | 1975-05-26 | 1976-12-16 | Noeller Hans Guenter Dr Med | ELECTRO-OPTIC, SUBSTANCE-CARE DETECTION OF NON-CELL-BONDED IMMUNE SUBSTANCES |
US4341957A (en) * | 1975-11-26 | 1982-07-27 | Analytical Radiation Corporation | Fluorescent antibody composition for immunofluorometric assay |
US4058732A (en) * | 1975-06-30 | 1977-11-15 | Analytical Radiation Corporation | Method and apparatus for improved analytical fluorescent spectroscopy |
US4228184A (en) * | 1976-05-10 | 1980-10-14 | E. R. Squibb & Sons, Inc. | Carboxyalkylacylamino acids |
US4259313A (en) * | 1978-10-18 | 1981-03-31 | Eastman Kodak Company | Fluorescent labels |
US4352751A (en) * | 1979-09-10 | 1982-10-05 | Analytical Radiation Corporation | Species-linked diamine triacetic acids and their chelates |
FR2470820A1 (en) * | 1979-11-30 | 1981-06-12 | Lafarge Sa | PROCESS FOR PRODUCING MINERAL FILLERS CONTAINING HYDRATED CALCIUM MONOCARBOALUMINATE |
SE425439B (en) * | 1981-04-30 | 1982-09-27 | Wallac Oy | IMMUNOLOGICAL ANALYSIS WITH LANTANIDE CHELAT COMPLEX AS MARKOR |
SE9502789D0 (en) * | 1995-08-09 | 1995-08-09 | Hans Tillander | Pressure infusion apparatus |
DE69622728D1 (en) * | 1995-09-15 | 2002-09-05 | Organon Teknika Bv | TOXOPLASMA GONDII GLYCOCONJUGATE |
-
1983
- 1983-03-15 SE SE8301395A patent/SE8301395L/en not_active Application Discontinuation
-
1984
- 1984-03-13 EP EP84901128A patent/EP0139675B1/en not_active Expired
- 1984-03-13 DE DE8484901128T patent/DE3462252D1/en not_active Expired
- 1984-03-13 JP JP59501184A patent/JPS60500767A/en active Granted
- 1984-03-13 WO PCT/SE1984/000089 patent/WO1984003698A1/en active IP Right Grant
-
1987
- 1987-02-20 US US07/016,789 patent/US4808541A/en not_active Expired - Lifetime
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB723316A (en) * | 1951-06-11 | 1955-02-09 | Frederick Charles Bersworth | Substituted alkylene polyamine acetic acid compounds |
DE2015022A1 (en) * | 1970-03-28 | 1971-10-28 | Joh. A. Benckiser Gmbh, Chemische Fabrik, 6700 Ludwigshafen | Agents for stabilizing the hardness of water, especially in cleaning solutions |
DE2233273A1 (en) * | 1971-07-07 | 1973-01-11 | Monsanto Co | CONDENSED POLYALKYLENE POLYAMINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE |
DE2150994A1 (en) * | 1971-10-13 | 1973-04-19 | Basf Ag | Aminopolycarboxylic acid salts - of alkalis in pure form by reacting alkali cyanide with formaldehyde or n-contg prim alcohol |
FR2196992A1 (en) * | 1972-08-21 | 1974-03-22 | Ciba Geigy Ag | |
US3994966A (en) * | 1972-09-28 | 1976-11-30 | The Board Of Trustees Of The Leland Stanford Junior University | Chelating agents |
DE2319047A1 (en) * | 1973-04-14 | 1974-10-31 | Hoechst Ag | ZWITTERIONIC PHOSPHORUS COMPOUNDS AND PROCESS FOR THE PREPARATION |
DE2357278A1 (en) * | 1973-11-16 | 1975-05-28 | Hoechst Ag | ANTIMICROBIAL INTERFACE-ACTIVE MEDIUM |
DE2611813A1 (en) * | 1975-03-20 | 1976-09-30 | Monsanto Co | IMINOALKYLIMINOPHOSPHONATE, METHOD FOR THEIR PRODUCTION AND USE |
DE2751943A1 (en) * | 1976-11-26 | 1978-06-01 | Ciba Geigy Ag | NEW AMINO-PHOSPHONATE |
DE2851898A1 (en) * | 1977-12-02 | 1979-06-07 | Montedison Spa | NEW DERIVATIVES OF N,N'-4-PIPERIDYL-TETRAALKYL-SUBSTITUTED ALKYLENEDIAMINE AND MATERIALS CONTAINING THEM |
DE2918842A1 (en) * | 1978-05-31 | 1979-12-13 | Rexolin Chem Ab | CHELATING AGENTS AND THEIR USE |
US4374120A (en) * | 1979-03-08 | 1983-02-15 | Wallac Oy | Fluorescence spectroscopy assay means with fluorescent chelate of a lanthanide |
EP0071564A1 (en) * | 1981-07-24 | 1983-02-09 | Schering Aktiengesellschaft | Paramagnetic complex salts, their preparation and their use in NMR diagnostics |
Non-Patent Citations (1)
Title |
---|
Patent Abstracts of Japan, abstract of JP 53-23924, published 1978-06-03 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987004523A1 (en) * | 1986-01-23 | 1987-07-30 | Robert Stephen Davidson | Binding assay and assay reagent |
US5811526A (en) * | 1986-01-23 | 1998-09-22 | Alusuisse Holdings A.G. | Binding assay and assay reagent |
US5099069A (en) * | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
EP0328529A1 (en) * | 1986-09-05 | 1989-08-23 | Otto A Gansow | Method for preparing polysubstituted diethylenetriaminepentaacetic acids. |
EP0328529A4 (en) * | 1986-09-05 | 1991-03-20 | Otto A. Gansow | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
EP0484989A1 (en) * | 1986-09-05 | 1992-05-13 | GANSOW, Otto A. | Polysubstituted diethylenetriamine chelates for forming a metal-chelate-protein conjugate |
WO1988002784A1 (en) * | 1986-10-17 | 1988-04-21 | Wallac Oy | Hybridization assay and means to be used in the assay |
US5256535A (en) * | 1986-10-17 | 1993-10-26 | Jyrki Ylikoski | Hybridization assay and means to be used in the assay |
WO1989012631A1 (en) * | 1988-06-24 | 1989-12-28 | The Dow Chemical Company | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
EP0353450A1 (en) * | 1988-06-24 | 1990-02-07 | The Dow Chemical Company | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
US5435990A (en) * | 1988-06-24 | 1995-07-25 | The Dow Chemical Company | Macrocyclic congugates and their use as diagnostic and therapeutic agents |
US5756065A (en) * | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
US5652361A (en) * | 1988-06-24 | 1997-07-29 | The Dow Chemical Company | Macrocyclic ligands and complexes |
EP0570022A2 (en) | 1988-10-31 | 1993-11-18 | The Dow Chemical Company | Chelants possessing ortho ligating functionality and complexes thereof |
EP0374947A1 (en) * | 1988-12-23 | 1990-06-27 | The Dow Chemical Company | Process for preparing isothiocyanato functionalized metal complexes |
WO1990014881A2 (en) * | 1989-05-26 | 1990-12-13 | Akzo N.V. | Chelating agents for attaching metal ions to proteins |
US5488126A (en) * | 1989-05-26 | 1996-01-30 | Akzo Nobel N.V. | Bifunctional chelating agents |
US5583219A (en) * | 1989-05-26 | 1996-12-10 | Akzo Nobel N.V. | Macrocyclic chelating agent |
EP0661267A1 (en) * | 1989-05-26 | 1995-07-05 | Akzo Nobel N.V. | Chelating agent for attaching metal ions to proteins |
US5808003A (en) * | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
WO1990014881A3 (en) * | 1989-05-26 | 1991-01-24 | Akzo Nv | Chelating agents for attaching metal ions to proteins |
EP0540975A1 (en) * | 1991-11-06 | 1993-05-12 | Bayer Ag | Diethylenetriamine derivatives and their use for diagnostic and therapeutic purposes |
WO1995018832A1 (en) * | 1994-01-07 | 1995-07-13 | Akzo Nobel N.V. | New polyaminocarboxylate chelators |
WO2001036973A2 (en) * | 1999-11-16 | 2001-05-25 | Otto Wolfbeis | Method for solubilising optical markers |
WO2001036973A3 (en) * | 1999-11-16 | 2002-02-14 | Otto Wolfbeis | Method for solubilising optical markers |
US11845976B2 (en) | 2019-08-27 | 2023-12-19 | SeLux Diagnostics, Inc. | Systems and methods for performing antimicrobial susceptibility testing |
Also Published As
Publication number | Publication date |
---|---|
SE8301395D0 (en) | 1983-03-15 |
EP0139675B1 (en) | 1987-01-28 |
US4808541A (en) | 1989-02-28 |
DE3462252D1 (en) | 1987-03-05 |
JPS60500767A (en) | 1985-05-23 |
SE8301395L (en) | 1984-09-16 |
JPH0377463B2 (en) | 1991-12-10 |
EP0139675A1 (en) | 1985-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0139675B1 (en) | Compound | |
RU2074859C1 (en) | Rare-earth metal cryptates as biological molecule fluorescent markers | |
US5346996A (en) | Rare earth cryptates, processes for their preparation, synthesis intermediates and application as fluorescent tracers | |
US5543524A (en) | Chemiluminescent acridinium salts | |
Mukkala et al. | The synthesis and use of activated N-benzyl derivatives of diethylenetriaminetetraacetic acids: alternative reagents for labeling of antibodies with metal ions | |
Takalo et al. | Synthesis of europium (III) chelates suitable for labeling of bioactive molecules | |
US4432907A (en) | Diamine acid fluorescent chelates | |
US4352751A (en) | Species-linked diamine triacetic acids and their chelates | |
US5332679A (en) | Method for specific binding assays using a releasable ligand | |
US4331590A (en) | β-Galactosyl-umbelliferone-labeled protein and polypeptide conjugates | |
US4404366A (en) | Beta-galactosyl-umbelliferone-labeled hapten conjugates | |
US4279992A (en) | Specific binding assay employing an enzyme-cleavable substrate as label | |
EP0285179B1 (en) | Fluorescent diagnostic assay, assay elements, and conjugates | |
JP3264757B2 (en) | Fluorescent compound | |
JPS58757A (en) | Method of executing immunity examination using no isotope, analytic substance labelled and kit used for such examination | |
JPH0637513B2 (en) | Digoxigenin derivative, production method thereof, labeled conjugate production method, nucleic acid detection method and digoxigenin conjugate | |
EP0220284B1 (en) | Novel fruorescent compounds and biological diagnostic devices | |
CA2058220A1 (en) | Fluorescent compound, complex, reagent, and specific binding assay employing said reagent | |
GB2041920A (en) | Intermediates useful in the synthesis of chemiluminescent phthalhydrazide-labelled conjugates | |
JP2572171B2 (en) | 1,2-Dioxetane as chemiluminescent label for organic and biological molecules | |
US5795987A (en) | Alkene intermediates for preparing 1,2-dioxetane compounds | |
AU595821B2 (en) | Homogeneous process for the luminescent determination and/or detection of an analyte in a medium susceptible of containingit | |
JPS61502681A (en) | Chemiluminescently labeled organic reagents and their use in the analysis of organic compounds | |
JP2002518413A (en) | New compounds | |
FI80801B (en) | KJJUGAT AV EN MONOCLONAL ANTIKROPP OCH ANVAENDNING. ELLER ETT FRAGMENT DAERAV OCH ETT KELATERANDE AEMNE, DESS FRAMSTAELLNING |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1984901128 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1984901128 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1984901128 Country of ref document: EP |